Argos Therapeutics (ARGS) Misses Q1 EPS by 1c

Argos Therapeutics (NASDAQ: ARGS) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $146.4 thousand versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M